555 related articles for article (PubMed ID: 32042196)
1. Peripheral CD8
Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
[TBL] [Abstract][Full Text] [Related]
2. Clonality of CD4
Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
Front Immunol; 2019; 10():1336. PubMed ID: 31275310
[TBL] [Abstract][Full Text] [Related]
3. Single-cell analysis of peripheral CD8
Khojandi N; Connelly L; Piening A; Hoft SG; Pherson M; Donlin MJ; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2023 Feb; 72(2):397-408. PubMed ID: 35907015
[TBL] [Abstract][Full Text] [Related]
4. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Gangaev A; Rozeman EA; Rohaan MW; Isaeva OI; Philips D; Patiwael S; van den Berg JH; Ribas A; Schadendorf D; Schilling B; Schumacher TN; Blank CU; Haanen JBAG; Kvistborg P
Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34670835
[TBL] [Abstract][Full Text] [Related]
6. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient.
Wieland A; Kamphorst AO; Adsay NV; Masor JJ; Sarmiento J; Nasti TH; Darko S; Douek DC; Xue Y; Curran WJ; Lawson DH; Ahmed R
Cancer Immunol Immunother; 2018 Nov; 67(11):1767-1776. PubMed ID: 30167863
[TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Luoma AM; Suo S; Williams HL; Sharova T; Sullivan K; Manos M; Bowling P; Hodi FS; Rahma O; Sullivan RJ; Boland GM; Nowak JA; Dougan SK; Dougan M; Yuan GC; Wucherpfennig KW
Cell; 2020 Aug; 182(3):655-671.e22. PubMed ID: 32603654
[TBL] [Abstract][Full Text] [Related]
9. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Daud AI; Loo K; Pauli ML; Sanchez-Rodriguez R; Sandoval PM; Taravati K; Tsai K; Nosrati A; Nardo L; Alvarado MD; Algazi AP; Pampaloni MH; Lobach IV; Hwang J; Pierce RH; Gratz IK; Krummel MF; Rosenblum MD
J Clin Invest; 2016 Sep; 126(9):3447-52. PubMed ID: 27525433
[TBL] [Abstract][Full Text] [Related]
10. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
11. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade.
Andrews MC; Duong CPM; Gopalakrishnan V; Iebba V; Chen WS; Derosa L; Khan MAW; Cogdill AP; White MG; Wong MC; Ferrere G; Fluckiger A; Roberti MP; Opolon P; Alou MT; Yonekura S; Roh W; Spencer CN; Curbelo IF; Vence L; Reuben A; Johnson S; Arora R; Morad G; Lastrapes M; Baruch EN; Little L; Gumbs C; Cooper ZA; Prieto PA; Wani K; Lazar AJ; Tetzlaff MT; Hudgens CW; Callahan MK; Adamow M; Postow MA; Ariyan CE; Gaudreau PO; Nezi L; Raoult D; Mihalcioiu C; Elkrief A; Pezo RC; Haydu LE; Simon JM; Tawbi HA; McQuade J; Hwu P; Hwu WJ; Amaria RN; Burton EM; Woodman SE; Watowich S; Diab A; Patel SP; Glitza IC; Wong MK; Zhao L; Zhang J; Ajami NJ; Petrosino J; Jenq RR; Davies MA; Gershenwald JE; Futreal PA; Sharma P; Allison JP; Routy B; Zitvogel L; Wargo JA
Nat Med; 2021 Aug; 27(8):1432-1441. PubMed ID: 34239137
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Tumeh PC; Harview CL; Yearley JH; Shintaku IP; Taylor EJ; Robert L; Chmielowski B; Spasic M; Henry G; Ciobanu V; West AN; Carmona M; Kivork C; Seja E; Cherry G; Gutierrez AJ; Grogan TR; Mateus C; Tomasic G; Glaspy JA; Emerson RO; Robins H; Pierce RH; Elashoff DA; Robert C; Ribas A
Nature; 2014 Nov; 515(7528):568-71. PubMed ID: 25428505
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
16. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Chowell D; Morris LGT; Grigg CM; Weber JK; Samstein RM; Makarov V; Kuo F; Kendall SM; Requena D; Riaz N; Greenbaum B; Carroll J; Garon E; Hyman DM; Zehir A; Solit D; Berger M; Zhou R; Rizvi NA; Chan TA
Science; 2018 Feb; 359(6375):582-587. PubMed ID: 29217585
[TBL] [Abstract][Full Text] [Related]
17. Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events.
Müller B; Bärenwaldt A; Herzig P; Zippelius A; Maul LV; Hess V; König D; Läubli H
Front Immunol; 2023; 14():1125111. PubMed ID: 37122748
[TBL] [Abstract][Full Text] [Related]
18. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
19. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
20. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P; Philips D; Kelderman S; Hageman L; Ottensmeier C; Joseph-Pietras D; Welters MJ; van der Burg S; Kapiteijn E; Michielin O; Romano E; Linnemann C; Speiser D; Blank C; Haanen JB; Schumacher TN
Sci Transl Med; 2014 Sep; 6(254):254ra128. PubMed ID: 25232180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]